Suppr超能文献

厄洛替尼与RNA干扰下调粘着斑激酶表达联合应用对胃癌的影响

Effects of combining erlotinib and RNA-interfered downregulation of focal adhesion kinase expression on gastric cancer.

作者信息

Feng Rui, Yang Sheng

机构信息

Teaching and Research Department of Oncology, Union Clinical Medical College of Fujian Medical University, Fujian, China.

Teaching and Research Department of Oncology, Union Clinical Medical College of Fujian Medical University, Fujian, China Department of Medical Oncology, Fujian Medical University Union Hospital, Fujian, China Fujian Key Laboratory of Translational Cancer Medicine, Fujian, China Fujian Medical University Stem Cell Research Institute, Fuzhou, Fujian, China

出版信息

J Int Med Res. 2016 Aug;44(4):855-64. doi: 10.1177/0300060516647550. Epub 2016 Jun 8.

Abstract

OBJECTIVE

To investigate the synergistic effects of combining erlotinib and RNA-interference downregulation of focal adhesion kinase (FAK) expression on the proliferation, apoptosis, invasion and migration of the human gastric adenocarcinoma cell line AGS.

METHODS

Cells were divided into five experimental groups: Group A, nontransfected control; Group B, transfected with empty vector; Group C, transfected with FAK-shRNA; Group D, erlotinib treatment; Group E, combination erlotinib treatment and transfected with FAK-shRNA. FAK protein levels were confirmed via Western blotting. Cell proliferation (CCK-8 assay, apoptosis (flow cytometry), cell invasion (transwell assay) and migration (scratch assay) were evaluated.

RESULTS

RNA interference significantly decreased FAK protein levels. Cell proliferation, invasion and migration were significantly lower in Groups C, D and E compared with Group A, and significantly lower in Group E than in Groups C and D.

CONCLUSIONS

RNA interference effectively silences FAK expression and inhibits malignant cell proliferation and invasion in gastric cancer cells. The effect of FAK inhibition is increased by co-treatment with erlotinib.

摘要

目的

探讨厄洛替尼与RNA干扰下调粘着斑激酶(FAK)表达相结合对人胃腺癌细胞系AGS增殖、凋亡、侵袭和迁移的协同作用。

方法

将细胞分为五个实验组:A组,未转染对照组;B组,转染空载体;C组,转染FAK-shRNA;D组,厄洛替尼处理;E组,厄洛替尼联合处理并转染FAK-shRNA。通过蛋白质印迹法确认FAK蛋白水平。评估细胞增殖(CCK-8法)、凋亡(流式细胞术)、细胞侵袭(Transwell法)和迁移(划痕试验)。

结果

RNA干扰显著降低了FAK蛋白水平。与A组相比,C组、D组和E组的细胞增殖、侵袭和迁移显著降低,E组显著低于C组和D组。

结论

RNA干扰有效沉默FAK表达并抑制胃癌细胞中的恶性细胞增殖和侵袭。与厄洛替尼联合处理可增强FAK抑制效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f889/5536637/8c62525485ea/10.1177_0300060516647550-fig1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验